ReviewNature reviews. Disease primers2019
Craniopharyngioma.
Review in Nature reviews. Disease primers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 284 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
284 citing papers in PubMed, 8 syntheses or guidelines pooled it, 507 citations in OpenAlex.
- Intracavitary irradiation with phosphorus-32 for cystic craniopharyngiomas: a systematic review and single-arm meta-analysis.Neurosurgical review · 2026Pooled it
- Pooled it
- Stereotactic radiosurgery for craniopharyngioma: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- The spectrum of radiation therapy options for craniopharyngioma: a systematic review.Journal of neuro-oncology · 2025Pooled it
- The oxytocin system in patients with craniopharyngioma: A systematic review.Frontiers in neuroendocrinology · 2025Pooled it
- Effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: an updated systematic review and meta-analysis.Pituitary · 2024Pooled it
- Endoscopic endonasal transsphenoidal approach improves endocrine function and surgical outcome in primary craniopharyngioma resection: a systematic review and meta-analysis.World journal of surgical oncology · 2024Pooled it
- Clinical, Radiographic and Histopathological Analysis of Craniopharyngiomas and Ameloblastomas: A Systematic Review.Head and neck pathology · 2022Pooled it
- High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial.Neuro-oncology · 2025Trial
- Trial
- Apc-deficient pituitary stem cells drive adamantinomatous craniopharyngioma through senescence-associated inflammation.EMBO molecular medicine · 2026Article
- Predicting early recurrence of craniopharyngioma using multi-omics radiomic modeling: a retrospective cohort study.Neurosurgical review · 2026Article
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer.Journal of clinical medicine · 2026Review
- Article
- Assessment of paediatric craniopharyngioma progression: a comparison of contrast-enhanced and non-contrast MRI.Neuroradiology · 2026Article
- Molecular therapy for papillary craniopharyngioma: a multi-institutional analysis of practice patterns across the RAPID Consortium.Journal of neuro-oncology · 2026Article
- Multidisciplinary Management of Pediatric Craniopharyngioma: From Diagnosis to Long-Term Outcomes.Biomedicines · 2026Review
- Article
- Early Findings from the Multicenter RAPID Consortium on Papillary Craniopharyngiomas.Journal of neurological surgery. Part B, Skull base · 2026Article
224 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
Abstract
Craniopharyngiomas are rare malformational tumours of low histological malignancy arising along the craniopharyngeal duct. The two histological subtypes, adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP), differ in genesis and age distribution. ACPs are diagnosed with a bimodal peak of incidence (5-15 years and 45-60 years), whereas PCPs are restricted to adults mainly in the fifth and sixth decades of life. ACPs are driven by somatic mutations in CTNNB1 (encoding β-catenin) that affect β-catenin stability and are predominantly cystic in appearance. PCPs frequently harbour somatic BRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.